Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study analyzes 188 Hypereosinophilic Syndrome (HES) patients, finding corticosteroids effective but imatinib superior for FIP1L1-PDGFRA mutations. Further trials are needed to optimize HES treatment.
Area Of Science
- Hematology
- Rare Diseases
- Clinical Research
Background
- Hypereosinophilic Syndrome (HES) is a rare, heterogeneous disorder characterized by persistent eosinophilia and organ damage.
- Limited published therapeutic data exists, primarily case reports and small series, except for mepolizumab trials.
Purpose Of The Study
- To compile and summarize baseline characteristics of a large, diverse Hypereosinophilic Syndrome cohort.
- To review treatment responses to conventional and novel therapies in HES patients.
Main Methods
- Retrospective chart review of clinical and laboratory data from 188 HES patients across 11 institutions (US and Europe).
- Data collected from January 2001 to December 2006.
Main Results
- 11% of patients had FIP1L1-PDGFRA mutations; 17% had aberrant T-cell populations.
- Corticosteroids showed high initial response rates (85%), with many patients on maintenance therapy.
- Hydroxyurea, IFN-alpha, and imatinib demonstrated efficacy, though imatinib was significantly more effective in FIP1L1-PDGFRA-positive patients (88% vs. 23%).
Conclusions
- This is the largest clinical analysis of Hypereosinophilic Syndrome patients to date.
- Findings offer valuable clinical insights and should encourage prospective trials for optimized HES treatment strategies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
This protocol describes the cell culturing of human midbrain dopaminergic neurons, followed by immunological staining and the generation of neuronal phenotypic profiles from acquired microscopic high-content images allowing the identification of phenotypic variations due to genetic or chemical...
In Parkinson's Disease (PD), Substantia Nigra (SNc) dopaminergic neurons degenerate, leading to motor dysfunction. Here we report a protocol for culturing ventral midbrain neurons from a mouse expressing eGFP driven by a Tyrosine Hydroxylase (TH) promoter sequence, harvesting individual fluorescent neurons from the cultures, and measuring their transcriptome using...
The causes of degeneration of midbrain dopaminergic neurons during Parkinson’s disease are not fully understood. Cellular culture systems provide an essential tool for study of the neurophysiological properties of these neurons. Here we present an optimized protocol, which can be utilized for in vitro modeling of...
This protocol describes two different environmental manipulations and a concurrent brain infusion protocol to study environmentally-induced brain changes underlying adaptive behavior and brain repair in adult...
Dopaminergic neurons play a vital regulatory role in the brain. Their loss is associated with Parkinson's disease. In this video, we show how to generate primary cultures of central dopaminergic neurons from embryonic mouse mesencephalon. Such cultures are useful to study the extreme vulnerability of these neurons to various...
Dopamine is distinctly regulated in the midbrain nuclei, which contain the cell bodies and dendrites of the dopamine neurons. Here we describe a dissection and sample-handling approach to maximize results, and thus conclusions and insights, on dopamine regulation in the midbrain nuclei of the substantia nigra (SN) and ventral tegmental area (VTA) in...